Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [3]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-32759 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Angiopoietin 2 Recombinant Rabbit Monoclonal Antibody (JM71-34)
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Antibody clone number
- JM71-34
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Cyclooxygenase inhibition attenuates brain angiogenesis and independently decreases mouse survival under hypoxia.
Seeger DR, Golovko SA, Grove BD, Golovko MY
Journal of neurochemistry 2021 Jul;158(2):246-261
Journal of neurochemistry 2021 Jul;158(2):246-261
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Angiopoietin 2 in different lysates using a Monoclonal antibody (Product #MA5-32759) at a dilution of 1:1,000. Positive control: Lane1: TF-1, Lane 2: Human liver tissue, Lane 3: Human placenta tissue.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Angiopoietin 2 of paraffin-embedded Human colon cancer tissue using a Angiopoietin-2 Monoclonal antibody (Product #MA5-32759). Counter stained with hematoxylin.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Angiopoietin 2 of paraffin-embedded Human placenta tissue using a Angiopoietin-2 Monoclonal antibody (Product #MA5-32759). Counter stained with hematoxylin.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Angiopoietin 2 of paraffin-embedded Mouse liver tissue using a Angiopoietin-2 Monoclonal antibody (Product #MA5-32759). Counter stained with hematoxylin.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- FIGURE 5 Alterations in brain angiogenic factor under hypoxia and COX inhibition with ketorolac. Mice were treated with saline (1 and 2) or ketorolac (3 and 4) using osmotic pumps (s.c.) under 24-hr or 10-day normoxia (1 and 3, 20% O 2 ) or hypoxia (2 and 4, 10% O 2 ). Values are mean +- standard deviation ( n (number of animals) =4) with individual values. Values that do not share the same letter are statistically different ( p < .05, one-way ANOVA with Tukey's post hoc test). (a) COX inhibition with ketorolac has no effect on HIF-1alpha levels under brain hypoxia as determined using ELISA. (b) COX inhibition with ketorolac has a slight but significant effect on brain VEGF and VEGFR2 levels under hypoxia. Brain VEGF was determined using ELISA. VEGFR2 were determined after western blot analysis and relative optical densities against actin are presented. Panels below bar graphs show representative blots for VEGFR2. (c). COX inhibition with ketorolac has no effect on brain bFGF and FGFR1 levels under hypoxia. Brain bFGF was determined using ELISA. pFGFR1 was determined after western blot analysis and relative optical densities against actin are presented. Panels below bar graphs show representative blots for pFGFR1. (d) COX inhibition with ketorolac has no effect on brain angiopoietin-2 under hypoxia. Brain angiopoietin-2 (Ang-2) was determined after western blot analysis and expressed as relative optical densities against actin. Panels below bar graphs show representative blot